A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
2don MSNOpinion
My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...
The Brighterside of News on MSN5d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patientsCAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
Interesting Engineering on MSN7d
US researchers develop next-gen CAR-T therapy to kill hard-to-treat cancersCART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...
Researchers uncover how leukemia drains T cells' energy, paving the way for stronger cancer immunotherapy and enhancing CAR T ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
Chromosomal Chaos Promotes Therapy Resistance in Leukemia Cells and Opens Up New ... Promising Cell Therapy Offers Hope for Relapsed or Refractory T-Cell Leukaemia Oct. 7, 2024 — Fratricide ...
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback